UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 30, 2009

SHENGTAI PHARMACEUTICALS, INC.
 (Exact name of registrant as specified in its charter)

     
Delaware
(State or other jurisdiction of incorporation)
000-51312
(Commission
File Number)
54-2155579
(IRS Employer
Identification No.)

   
  Changda Road East
Development District, Changle County
Shandong, PRC 262400
 (Address of principal executive offices)
262400
(Zip Code)

Registrant’s telephone number, including area code: 011-86-536-218-2777

Benjamin Tan, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 Floor
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communication s pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 

Item 5.02      Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Directors

On November 30, 2009, our Chief Financial Officer, Ms. Yiru Shi resigned from her position as, Chief Financial Officer with immediate effect.   Ms. Shi cited the desire to pursue other career goals as the reason for her resignation.  On the same day, the Company’s board of directors accepted her resignation.

Also on November 30, 2009, the Company’s board of directors appointed Mr. Yongqiang Wang to assume the position of the Company’s new Chief Financial Officer with immediate effect.

Mr. Wang’s annual salary is $96,000 payable monthly and in accordance with customary payroll practices.

Mr. Wang, 40, graduated with an Associates degree from the Shandong Economic and Management Institute. He joined Weifang Shengtai in April 2006 as the assistant to the General Manager of the Accounts Department and was in charged of the finance department. He assumed the position of Deputy General Manager of the Accounts Department in February 2007. Prior to joining us, Mr. Wang worked as a financial manager for various enterprises.  Mr. Wang is also a director of the Company and has held the position since May 15, 2007.

There are no family relationships between Mr. Wang and our directors or executive officers.


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
SHENGTAI PHARMACEUTICALS, INC.
   
   
Dated: November 30, 2009
 
 
By: /s/ Qingtai Liu
 
Name: Qingtai Liu
 
Title: Chief Executive Officer
 
 
 

 
 
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Shengtai Pharmaceutical (GM) Charts.
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Shengtai Pharmaceutical (GM) Charts.